Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus

Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus

Objective: To compare the efficacy and safety of the once-daily prandial glucagon-like peptide-1 receptor agonist lixisenatide with the dipeptidyl peptidase-4 inhibitor sitagliptin in patients aged <50 years affected by obesity and type 2 diabetes mellitus (T2DM). Materials and methods: This was...

Full description

Bibliographic Details
Main Authors: Luc Van Gaal, Elisabeth Souhami, Tianyue Zhou, Ronnie Aronson
Format: Article
Language:English
Published: Elsevier 2014-06-01
Series:Journal of Clinical & Translational Endocrinology
Subjects:
Glycated hemoglobin (HbA1c)
Body weight
Postprandial plasma glucose (PPG)
Online Access:http://www.sciencedirect.com/science/article/pii/S2214623714000118

Similar Items

Similar Items